Literature DB >> 35673849

Toward evaluation of disseminated effects of medications for opioid use disorder within provider-based clusters using routinely-collected health data.

Ashley Buchanan1, Tianyu Sun1, Jing Wu2, Hilary Aroke1, Jeffrey Bratberg1, Josiah Rich3, Stephen Kogut1, Joseph Hogan4.   

Abstract

Routinely-collected health data can be employed to emulate a target trial when randomized trial data are not available. Patients within provider-based clusters likely exert and share influence on each other's treatment preferences and subsequent health outcomes and this is known as dissemination or spillover. Extending a framework to replicate an idealized two-stage randomized trial using routinely-collected health data, an evaluation of disseminated effects within provider-based clusters is possible. In this article, we propose a novel application of causal inference methods for dissemination to retrospective cohort studies in administrative claims data and evaluate the impact of the normality of the random effects distribution for the cluster-level propensity score on estimation of the causal parameters. An extensive simulation study was conducted to study the robustness of the methods under different distributions of the random effects. We applied these methods to evaluate baseline prescription for medications for opioid use disorder among a cohort of patients diagnosed with opioid use disorder and adjust for baseline confounders using information obtained from an administrative claims database. We discuss future research directions in this setting to better address unmeasured confounding in the presence of disseminated effects.
© 2022 John Wiley & Sons Ltd.

Entities:  

Keywords:  dissemination; health data; interference; medication for opioid use disorder; mixed effects models; opioid use disorder

Mesh:

Year:  2022        PMID: 35673849      PMCID: PMC9288976          DOI: 10.1002/sim.9427

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.497


  67 in total

1.  Trends in naloxone prescriptions prescribed after implementation of a National Academic Detailing Service in the Veterans Health Administration: A preliminary analysis.

Authors:  Mark Bounthavong; Michael A Harvey; Daina L Wells; Sarah J Popish; Julianne Himstreet; Elizabeth M Oliva; Chad L Kay; Marcos K Lau; Priyanka P Randeria-Noor; Andrea G Phillips; Melissa L D Christopher
Journal:  J Am Pharm Assoc (2003)       Date:  2017-01-11

2.  Toward Causal Inference With Interference.

Authors:  Michael G Hudgens; M Elizabeth Halloran
Journal:  J Am Stat Assoc       Date:  2008-06       Impact factor: 5.033

3.  The duration and correlates of addiction and treatment careers.

Authors:  Michael L Dennis; Christy K Scott; Rodney Funk; Mark A Foss
Journal:  J Subst Abuse Treat       Date:  2005

4.  A Recipe for inferference: Start with Causal Inference. Add Interference. Mix Well with R.

Authors:  Bradley C Saul; Michael G Hudgens
Journal:  J Stat Softw       Date:  2017-11-29       Impact factor: 6.440

5.  Cost and utilization outcomes of opioid-dependence treatments.

Authors:  Onur Baser; Mady Chalk; David A Fiellin; David R Gastfriend
Journal:  Am J Manag Care       Date:  2011-06       Impact factor: 2.229

6.  A random-effects ordinal regression model for multilevel analysis.

Authors:  D Hedeker; R D Gibbons
Journal:  Biometrics       Date:  1994-12       Impact factor: 2.571

7.  On causal inference in the presence of interference.

Authors:  Eric J Tchetgen Tchetgen; Tyler J VanderWeele
Journal:  Stat Methods Med Res       Date:  2010-11-10       Impact factor: 3.021

8.  Buprenorphine in the United States: Motives for abuse, misuse, and diversion.

Authors:  Howard D Chilcoat; Halle R Amick; Molly R Sherwood; Kelly E Dunn
Journal:  J Subst Abuse Treat       Date:  2019-07-12

9.  A General Framework for Considering Selection Bias in EHR-Based Studies: What Data Are Observed and Why?

Authors:  Sebastien Haneuse; Michael Daniels
Journal:  EGEMS (Wash DC)       Date:  2016-08-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.